QbD Group
    点播网络研讨会

    IVDR Extension Explained: Tips & Strategies

    The journey towards adopting the IVD regulations introduced in 2017 has been ongoing for some time, presenting challenges for many in the industry. This session will provide you with the latest updates on the IVDR extension and its impact on your daily operations and long-term strategies. Don’t miss this opportunity to gain valuable insights directly from an expert at the forefront of the field.

    随时观看
    60 分钟
    In Vitro Diagnostics
    Chinese

    The journey towards adopting the IVD regulations introduced in 2017 has been ongoing for some time, presenting challenges for many in the industry. Acknowledging the potential disruption that can be caused by devices no longer being available, the European Commission introduced initiatives last year to ensure continuity in devices on the market and minimize the impact on patients. Now, as we enter 2024, they are reinforcing these efforts with new measures to facilitate a seamless transition for specific IVDs.

    This session will provide you with the latest updates on the IVDR extension and its impact on your daily operations and long-term strategies. Don’t miss this opportunity to gain valuable insights directly from an expert at the forefront of the field.

    Watch the webinar on demand

    What you'll learn

    • Understanding the proposal
    • Understanding the implications of the IVDR extension and the conditions to be met to make use of the new extended transitional provisions
    • The impact of the gradual roll-out of EUDAMED
    • Information obligation in case of interruption of supply
    • Strategic planning for compliance: Learn strategies to navigate the IVDR transition effectively, including tips for adjusting your day-to-day operations and long-term planning
    • Expert Q&A to address your specific questions

    向最优秀的人学习

    演讲者

    Join us as our expert speakers share valuable insights and practical knowledge drawn from extensive industry experience.

    Kirsten Van Garsse

    Kirsten Van Garsse

    Director Authorised Representative Services & Manager IVD - Regulatory Affairs

    Kirsten Van Garsse obtained her Master’s degree in Biomedical Sciences in 2002 from the Vrije Universiteit Brussel (VUB) and has amassed extensive experience in the In Vitro Diagnostic Medical Device Industry. She joined Qarad, now part of the QbD Group, a consulting company specialized in Regulatory Affairs and Quality Systems for the IVD and Medical Device industry, at the end of 2017. In her role as Director of Authorized Representative Services & Manager of IVD Regulatory Affairs, Kirsten applies her wealth of experience to Regulatory Affairs projects, adeptly translating regulations into compliant business processes and applications. Additionally, she oversees the various Representation Services offered by Qarad, ensuring clients receive expert support in navigating regulatory requirements.

    Anne Paulussen

    Anne Paulussen

    Senior Consultant IVD - Regulatory Affairs

    Anne Paulussen brings nearly 15 years of experience in the pharmaceutical sector. Anne’s extensive experience in both the pharmaceutical and in vitro diagnostics (IVDs) sectors has given her a profound understanding of the interplay between pharmaceuticals and diagnostics. With expertise spanning both fields, Anne offers valuable insights that enhance her contributions to the industry, especially in the field of companion diagnostics. Prior to joining Qarad in 2022 as a Senior Regulatory Consultant for IVDs, Anne served as a Global Regulatory Device Leader at Sanofi, working on drug-device combinations. In her current role, Anne leverages her expertise to advise CROs and pharmaceutical companies on IVDR compliance, regulatory intelligence, and comprehensive training for IVD manufacturers across all facets of IVDR implementation.

    Register here

    Discover how we can help

    Explore IVD Regulatory Affairs

    Keep watching

    More webinars

    订阅生命科学领域的最新动态

    专家观点直达您的收件箱——选择您的兴趣。

    绝无垃圾邮件。随时取消订阅。